Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1032069
Abstract: ABT-199 (venetoclax) is the first-in-class selective B-cell lymphoma 2 (BCL2) inhibitor, which is known to be ineffective towards liver cancer cells. Here, we investigated the efficacy and the underlying molecular processes of the sensitization effect…
read more here.
Keywords:
hepatoma;
sensitization effect;
abt 199;
persimmon leaves ... See more keywords